Oncologists whose research and treatment innovations have changed the course of cancer care will join the elite roster of medical pioneers named OncLive's Giants of Cancer Care when the 2015 honorees are announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.
As immunotherapy agents enter into greater clinical use in oncology, clinicians are learning to manage immune-related adverse events related to the mechanism of action of these new drugs.
A fourth of patients with advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.
A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.
A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.
Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.
Individuals chosen by this elite committee to receive the 2015 Giants of Cancer Care award for outstanding contributions in the field of oncology will be announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.
In 1974, Patrick C. Walsh, MD, took charge of the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland, and spent the next few decades refining the radical prostatectomy into a safe, effective, and tolerable procedure, one that has not only extended countless lives but has also preserved quality of life.
Deliberations are complete and final votes cast for the winners of the 2015 Giants of Cancer Care Award recognizing individuals who have achieved landmark success in the field of oncology.
The Emperor of All Maladies documentary did a great job of capturing the innovative genius of mankind and the heroism of both oncologists and the patients who participated in their research.
The president of Medicine & Science at Cancer Treatment Centers of America and editor-in-chief of OncologyLive magazine argues the FDA's recent approval of olaparib (Lynparza) for women with BRCA-mutated advanced ovarian cancer is too restrictive and should be offered to many more patients.
Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma.
Jedd D. Wolchok, MD, PhD, played an important role in the development of ipilimumab, the first drug to target an immune checkpoint as an anticancer strategy. He was honored in the Melanoma category with a 2014 Giants of Cancer Care® award.
Dr. Matthew J. Carpenter, an associate professor at the Medical University of South Carolina and researcher with the MUSC Hollings Cancer Center, is the recipient of the 2015 Governor's Young Scientist Award for Excellence in Scientific Research.
Alok A. Khorana, MD, specializes in predictive factors in gastrointestinal oncology and in cancer-associated thrombosis at the Cleveland Clinic. He provided insight on gastric cancer research in an interview with OncLive.
OncLive and the University of Cincinnati Cancer Institute announced today that they've joined forces to share news about the Institute's latest developments through OncLive's Strategic Alliance Partnership program.
Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.
OncLive and Georgetown Lombardi Comprehensive Cancer Center have teamed up to highlight leading-edge cancer research and innovative cancer treatment programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.
OncLive today joins with The University of Texas MD Anderson Cancer Center in a partnership to increase awareness of the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.
The FDA has approved its first biosimilar, Zarxio, for all five its counterpart Neupogen's authorized indications.
OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.
A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.
Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.
OncLive today welcomes the Medical University of South Carolina's Hollings Cancer Center as a partner in promoting the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.
Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.
OncLive and Tulane Cancer Center at the Tulane University School of Medicine have joined forces to promote awareness of new developments in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced today.
OncLive today welcomes Rutgers Cancer Institute of New Jersey as a partner in promoting awareness of the most recent advances in cancer care through OncLive's Strategic Alliance Partnership program
OncLive® and Fox Chase Cancer Center, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center that is part of the Temple University Health System in Philadelphia, announced that they have joined forces to raise awareness of significant oncology research and clinical practice news through OncLive's Strategic Alliance Partnership program.
A Spanish foundation has awarded a major scientific prize to Yale researcher Joseph Schlessinger and two colleagues in recognition of their work leading to the first personalized treatments for cancer. The 2015 Frontiers of Knowledge Award in Biomedicine from the Madrid-based BBVA Foundation includes a €400,000 cash priz
OncLive® welcomes the University of Chicago Medicine Comprehensive Cancer Center as a partner in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program.
